A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors

Breast Cancer Clinical Trial

Official title:

A Multi-Center, Open Label Phase 1/2 Study of CYT-0851 in Patients With Relapsed/Refractory B-Cell Malignancies and Advanced Solid Tumors

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT03997968
• Other study ID #: CYT-0851-01
• Status: Active, not recruiting
• Phase: Phase 1/Phase 2
• Start date: October 9, 2019
• Est. completion date: December 30, 2024

Study information

• Verified date: February 2023
• Source: Cyteir Therapeutics, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This clinical trial is an interventional, active-treatment, open-label, multi-center, Phase 1/2 study. The study objectives are to assess the safety, tolerability and pharmacokinetics (PK) of CYT-0851 in patients with relapsed/refractory B-cell malignancies and advanced solid tumors and to identify a recommended Phase 2 dose as a monotherapy and in combination with chemotherapy for evaluation in these patients.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 170
• Est. completion date: December 30, 2024
• Est. primary completion date: July 30, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Key Phase 1 Inclusion Criteria

1. Male or female =18 years of age at time of informed consent.

1. Female subjects of childbearing potential must be non-lactating, not pregnant as confirmed by a negative serum pregnancy test at most 30 days before enrollment and within 72 hours before the first administration of CYT-0851

2. Female subjects of childbearing potential must not donate ova during the study and for at least 90 days after the last dose of study drug and must agree to continue using an effective method of contraception during the screening period to first study drug administration until 90 days after the last dose of study drug

3. Male subjects who have not had a vasectomy must agree to use an effective method of contraception during the study and until 90 days after the last dose of the study drug, and to not donate sperm during the study and for at least 90 days after the last dose of study drug

2. ECOG Performance Status of 0-1

3. Measurable disease defined by disease-specific response criteria

4. Histologically-proven B cell malignancies, meeting the following criteria:

1. Relapsed, refractory B-cell non-Hodgkin lymphoma requiring therapy, after at least two prior therapies, and if transplanted, then at least 3-month post autologous stem cell transplant and if CART-treated, then evidence of progression no sooner than 3 months post CART treatment, or

2. Relapsed, refractory chronic lymphocytic leukemia requiring therapy after at least two prior therapies, including BTK and BCL-2 inhibitor therapy (unless ineligible for such therapy), or

3. For multiple myeloma, relapsed or progressive on or after treatment with at least three prior therapies that included a proteasome inhibitor, an imide, daratumumab, and if transplant eligible, a bone marrow transplant (unless unfit for transplant), or

5. Histologically-proven solid tumor meeting the following criteria:

1. Patients must have failed, refused, or not be eligible for further standard therapies (including chemotherapy, hormonal therapies, Her-2 directed therapies, as appropriate) expected to provide clinical benefit, and meeting the following criteria

2. Metastatic breast cancer (including ER/PR positive or negative, Her-2 positive and negative, triple negative), treated with at least 1 prior therapy for metastatic disease, or

3. Recurrent squamous cell carcinoma of the head and neck (HNSCC) (dose escalation) or human papilloma virus positive (HPV+) HNSCC (dose-escalation and backfill), treated with at least 1 prior therapy, or

4. Ovarian cancer, progressive after treatment with at least prior platinum-based chemotherapy, and therapy with a PARP inhibitor or

5. Soft tissue sarcoma, treated with at least one line of prior systemic therapy, or

6. Recurrent metastatic or locally advanced pancreatic cancer after first line chemotherapy (backfill or combination patients only) or

7. Histologically-proven advanced small-cell lung cancer (SCLC) (monotherapy backfill patients only).

1. Patients with mixed histology are not allowed

2. Prior treatment with platinum containing chemotherapy regimen with no evidence of progression within 90 days of last dose of platinum agent and anti-PD-(L)1 unless contraindicated

3. At least 1 prior line of chemotherapy, but no more than 3 prior lines of therapy

6. Understands the procedures and requirements of the study and provides written informed consent and authorization for protected health information disclosure

7. Willing and able to comply with the requirements of the study protocol

8. Site of disease amenable to a biopsy and willing to undergo biopsy required for backfill, or for dose-escalation if considered unsafe (approval to participate in the study required by the Medical Monitor) provide an archival sample = 12 months old Key Phase 2 Inclusion Criteria

1. Male or female =18 years of age at time of informed consent.

1. Female subjects of childbearing potential must be non-lactating, not pregnant as confirmed by a negative serum pregnancy test at most 30 days before enrollment and within 72 hours before the first administration of CYT-0851

2. Female subjects of childbearing potential must not donate ova during the study and for at least 90 days after the last dose of study drug and must agree to continue using, an effective method of contraception during the screening period to first study drug administration until 90 days after the last dose of study drug

3. Male subjects who have not had a vasectomy must agree to use an effective method of contraception during the study and until 90 days after the last dose of the study drug, and to not donate sperm during the study and for at least 90 days after the last dose of study drug

2. ECOG Performance Status of 0-1

3. Measurable disease defined by disease-specific response criteria

4. Site of disease amenable to a biopsy and willing to undergo a biopsy for the determination of biomarker status, or, if considered unsafe (approval to participate in the study required by the Medical Monitor), archival sample = 12 months old for determination of biomarker status.

5. Biomarker positive on recent biopsy or bone marrow sample if required for the specific cohort.

6. Histologically-proven B cell malignancies, meeting the following criteria:

1. DLBCL Cohort

1. Histologically-documented DLBCL or double hit lymphoma (B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma with BCL2 and MYC translocations (WHO Classification)

2. Progressing on or after treatment with at least two prior lines of therapy, including R-CHOP or equivalent first line therapy

3. If transplanted, then at least 3-month post autologous stem cell transplant

4. If CART-treated, then evidence of progression no sooner than 3 months post CART treatment

2. MCL Cohort

1. Histologically-documented MCL

2. Any stage at diagnosis

3. Progressing on or after treatment with at least 2 prior lines of therapy, including a Bruton tyrosine kinase (BTK) inhibitor, after a 14-day washout period

3. Multiple Myeloma Cohort

1. Relapsed or progressing after treatment with at least 3 prior therapies that include a proteasome inhibitor, an Immunomodulatory imide drug (IMiD), daratumumab, and, if transplant eligible, a bone marrow transplant (unless unfit for transplant)

7. Or Histologically-proven solid tumors meeting the following criterial

1. Patients must have failed, refused, or not be eligible for further standard therapies (including chemotherapy, hormonal therapies, Her-2 directed therapies, as appropriate) expected to provide clinical benefit, and meeting the following criteria

2. Triple Negative Breast Cancer Cohort

1. Histologically-documented triple negative breast cancer, ER/PR negative (defined as <10% of cells expressing hormonal receptors via immunohistochemistry (IHC) analysis), and HER2-negative, defined as either

of the following by local laboratory assessment:

• In situ hybridization (ISH) non-amplified (ratio of HER2 to CEP17 < 2.0 or single probe average HER2 gene copy number < 4 signals/cell), or
• IHC 0 or IHC 1+

2. At least 1 prior line of chemotherapy, but no more than 5 prior lines of chemotherapy

3. Ovarian Cancer Cohort

1. Histologically-proven metastatic epithelial ovarian cancer

2. Prior treatment with a platinum containing chemotherapy regimen

3. At least 1 prior line of therapy, but no more than 5 prior lines of chemotherapy

4. Pancreatic Cancer Cohort

1. Histologically-proven metastatic or locally advanced pancreatic cancer

2. At least 1 prior line of chemotherapy but no more than 4 prior lines of systemic therapy

5. Soft Tissue Sarcoma Cohort 1) Histologically-proven advanced soft-tissue sarcoma excluding all types of adipocytic sarcoma and GIST 2) At least 1 prior line of systemic therapy (unless no standard of care exists), but no more than 5 prior lines of systemic therapy

8. Follicular Lymphoma Cohort

1. Histologically-documented follicular lymphoma

2. Relapsed, refractory follicular lymphoma requiring therapy, after at least two prior therapies, and if CART-treated, then evidence of progression no sooner than 3 months post CART treatment

9. Understands the procedures and requirements of the study and provides written informed consent and authorization for protected health information disclosure

10. Willing and able to comply with the requirements of the study protocol Key Exclusion Criteria

1. Medical Conditions

1. Known history of HIV

2. Known history of viral hepatitis B unless HBV viral load is below the limit of quantification and off viral suppressive therapy

3. Know history of hepatitis C unless antiviral treatment with curative intent completed and HCV viral load is below the limit of quantification.

4. Myocardial infarction or stroke within 6 months

5. Uncontrolled hypertension (systolic blood pressure (SBP) > 160 or diastolic blood pressure (DBP) >100 on maximal medical therapy)

6. History of interstitial pulmonary disease

7. Unresolved pneumonitis

8. Grade = 3 neuropathy

9. Known active central nervous system (CNS) metastases. Subjects with previously treated CNS metastases may participate as long as clinically and radiologically stable for at least 4 weeks after treatment, have no evidence of new or enlarging lesions and are off steroids and asymptomatic for 28 days prior to dosing with study medication

10. Known history of meningeal involvement or meningeal carcinomatosis

11. Spinal cord compression not definitively treated with surgery and/or radiation, or previously diagnosed and treated spinal cord compression without evidence that disease has been clinically stable for > 2 weeks prior to screening visit

12. Presence of clinically significant cataracts

13. Second malignancy, except treated basal cell or localized squamous skin carcinomas, localized prostate cancer, or other malignancy that is in remission or stable and for which patients have not been on active anti-cancer therapy for 2 years

14. Pregnant or lactating. If ß-HCG is elevated, eligible if ultrasound confirms absence of a pregnancy.

15. Dementia or significantly altered metal status

16. Bowel obstruction requiring medical management less than 4 weeks prior to screening

17. Inability to tolerate oral intake that includes 2 full meals per day (or equivalent) or swallow pills.

18. Recurrent ascites requiring paracentesis more frequently than every 4 weeks or within 14 days of screening.

19. Weight loss of more than 10% over the preceding 3 months prior to screening

2. Prior/Concomitant Therapy

1. Prior allogeneic stem cell transplant

2. On systemic antibiotic, antifungal or anti-viral therapy

3. White blood cell (WBC) growth factors administered within 14 days of screening visit

4. Cancer therapy within 14 days prior to treatment with study drug

5. On narrow therapeutic index medications that are sensitive substrates of CYP3A, P-gp or BCRP (or caution is warranted with approval by the Sponsor).

6. On any drug known to prolong QTc interval (eg, certain antiarrhythmic, antimicrobials) that cannot be discontinued or interrupted 72 hours before the Day 1 dose through Day 2, and 72 hours before the Day 15 dose until Day 16 (BID dosing) or the Day 22 dose until Day 23 (QD dosing), in Cycle 1 (see Section 7.6.1 for a list of drugs).

7. On systemic corticosteroid treatment for non-tumor indication at a daily dose equivalent to >10mg of Prednisone

3. Prior/Concurrent Clinical Study Experience a. Participation in another clinical trial (unless in the observation phase, or an observational study), or exposure to any investigational agent within 14 days prior to treatment with study drug

4. Laboratory assessments

1. Complete blood count (CBC):

Monotherapy and Chemotherapy Combinations 1 and 2:

1. ANC < 1.0 × 10^9/L

2. PLT < 75 × 10^9/L

3. Hgb < 9.0 g/dL Chemotherapy Combination Group 3: 1) ANC < 1.5 × 10^9/L 2) PLT < 100 × 10^9/L 3) Hgb < 9.0 g/dL

Monotherapy and Chemotherapy Combination Groups 1 and 2:

2. Calculated Creatinine clearance (Cockcroft-Gault) < 40 mL/min Chemotherapy Combination Group 3: b. Calculated Creatinine clearance (Cockcroft-Gault) < 50 mL/min c. Hepatic function

1. AST > 2.0 × ULN

2. ALT > 2.0 × ULN d. Total bilirubin > 1.5 x ULN e. Albumin < 2.8 g/dL 5. ECG Exclusion a. Screening QTc interval > 450 milliseconds for males and QTc > 470 ms for females (corrected by Fridericia) 6. Other Exclusions

1. Unwilling or unable to make all planned study visits

2. Unwilling or unable to provide a recent biopsy or bone marrow sample prior to enrollment and during study; Note: certain exceptions may be permitted allowing archival specimens prior to treatment or for subjects where a specimen is not required for biomarker positive testing

3. Significant medical diseases or conditions, as assessed by the Investigators and Cyteir that would substantially increase the risk-benefit ratio of participating in the study. This includes but is not limited to acute myocardial infarction, arterial thrombosis, significant gastrointestinal bleed, or unstable angina within the last 6 months uncontrolled diabetes mellitus, current active infections, severely immunocompromised state, and congestive heart failure New York Heart Association (NYHA) Class III-IV, left ventricular ejection fraction (LVEF) < 40% d: Chemotherapy Combination Group 3 only: known history of dhydropyrimidine dehydrogenase deficiency

Related Conditions & MeSH terms

• Breast Cancer
• Breast Neoplasms
• CLL
• DLBCL
• Follicular Lymphoma
• Head and Neck Cancer
• Lymphoma
• Lymphoma, Mantle-Cell
• Malignancy
• Mantle Cell Lymphoma
• Multiple Myeloma
• Neoplasms
• Non-hodgkin Lymphoma
• Ovarian Cancer
• Pancreatic Cancer
• Sarcoma
• Small Cell Lung Cancer
• Small Cell Lung Carcinoma
• Soft Tissue Sarcoma
• Squamous Cell Carcinoma of Head and Neck
• Triple Negative Breast Cancer
• Triple Negative Breast Neoplasms

Intervention

Drug:
• CYT-0851
Part A and B: Daily oral doses of CYT-0851 for 28 day cycles
• CYT-0851 in combination with gemcitabine
Part D: Daily oral doses of CYT-0851 for 28 days in combination with gemcitabine
• CYT-0851 in combination with capecitabine
Part E: Daily oral doses of CYT-0851 for 21 days in combination with capecitabine
• CYT-0851 in combination with rituximab and bendamustine
Part C: Daily oral doses of CYT-0851 for 28 days in combination with rituximab and bendamustine

Locations

Country	Name	City	State
United States	University of Michigan	Ann Arbor	Michigan
United States	Dana Farber Cancer Institute	Boston	Massachusetts
United States	Massachusetts General Hospital	Boston	Massachusetts
United States	Sarah Cannon Research Institute at HealthONE	Denver	Colorado
United States	John Theurer Cancer Center at HUMC	Hackensack	New Jersey
United States	The University of Texas MD Anderson Cancer Center	Houston	Texas
United States	Medical College of Wisconsin	Milwaukee	Wisconsin
United States	Sarah Cannon Research Institute at Tennessee Oncology	Nashville	Tennessee
United States	NYU Langone Health	New York	New York
United States	Oklahoma University-Stephenson Cancer Center	Oklahoma City	Oklahoma
United States	Thomas Jefferson University, Sidney Kimmel Cancer Center	Philadelphia	Pennsylvania
United States	Mayo Clinic	Rochester	Minnesota
United States	University of California San Francisco	San Francisco	California
United States	Florida Cancer Specialists and Research Institute	Sarasota	Florida
United States	University of Washington Seattle Cancer Center	Seattle	Washington
United States	Stanford Comprehensive Cancer Center	Stanford	California

Sponsors (1)

Lead Sponsor	Collaborator
Cyteir Therapeutics, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Part A: Incidence of dose limiting toxicity	Cycle 1 Dose limiting toxicities and determination of the maximum tolerated dose	28 Days
Primary	Part B: Objective response rate	clinical benefit as determined by investigator assessments of tumor response	24 Weeks
Primary	Part C: Incidence of dose limiting toxicity	Cycle 1 Dose limiting toxicities and determination of the maximum tolerated dose in combination with rituximab and bendamustine	28 Days
Primary	Part D: Incidence of dose limiting toxicity	Cycle 1 Dose limiting toxicities and determination of the maximum tolerated dose in combination with gemcitabine	28 Days
Primary	Part E: Incidence of dose limiting toxicity	Cycle 1 Dose limiting toxicities and determination of the maximum tolerated dose in combination with capecitabine	21 Days
Secondary	Part A: Incidence of adverse events and other safety measures	incidence of adverse events changes in laboratory parameters, vital signs and ECGs; • Establish the PK of CYT-0851 Evaluate the type and frequency of adverse events	28 Days
Secondary	Part C: Incidence of adverse events and other safety measures	incidence of adverse events changes in laboratory parameters, vital signs and ECGs; • Establish the PK of CYT-0851 Evaluate the type and frequency of adverse events	28 Days
Secondary	Part D: Incidence of adverse events and other safety measures	incidence of adverse events changes in laboratory parameters, vital signs and ECGs; • Establish the PK of CYT-0851 Evaluate the type and frequency of adverse events	28 Days
Secondary	Part E: Incidence of adverse events and other safety measures	incidence of adverse events changes in laboratory parameters, vital signs and ECGs; • Establish the PK of CYT-0851 Evaluate the type and frequency of adverse events	21 Days
Secondary	Part A: Assessment of pharmacokinetic parameters	Summarize PK parameters including Cmax, AUC and tmax	Phase 1: 12 months
Secondary	Part C: Assessment of pharmacokinetic parameters	Summarize PK parameters including Cmax, AUC and tmax	Phase 1: 12 months
Secondary	Part D: Assessment of pharmacokinetic parameters	Summarize PK parameters including Cmax, AUC and tmax	Phase 1: 12 months
Secondary	Part E: Assessment of pharmacokinetic parameters	Summarize PK parameters including Cmax, AUC and tmax	Phase 1: 12 months
Secondary	Part B: Assessment of pharmacokinetic parameters	Summarize PK parameters including Cmax, AUC and tmax	Phase 1: 12 months
Secondary	Part A: Objective response rate	clinical activity as assessed by investigator assessment of objective response and duration of response	24 months
Secondary	Part C: Objective response rate	clinical activity as assessed by investigator assessment of objective response and duration of response	24 months
Secondary	Part D: Objective response rate	clinical activity as assessed by investigator assessment of objective response and duration of response	24 months
Secondary	Part E: Objective response rate	clinical activity as assessed by investigator assessment of objective response and duration of response	24 months
Secondary	Part B: Anti-tumor activity and by DOR	Antitumor activity as assessed by duration of response	24 months
Secondary	Part B: Anti-tumor activity by PFS	Antitumor activity as assessed by progression free survival	24 months
Secondary	Part B: Anti-tumor activity by DCR	Antitumor activity as assessed by disease control rate	24 months
Secondary	Part B: Anti-tumor activity by OS	Antitumor activity as assessed by overall survival	24 months
Secondary	Part B: Safety assessment	Safety as determined by incidence of AEs and SAEs and changes in laboratory, vitals and ECG findings	24 months